RETATRUTIDE 10mg VIAL – GLP-1, GIP & GLUCAGON AGONIST

WHAT IS RETATRUTIDE:

Retatrutide is a triple receptor agonist that activates GLP-1, GIP, and glucagon receptors. By combining these pathways, it improves insulin secretion, lowers blood glucose, reduces appetite, and increases calorie burning through a higher metabolic rate. It is used for type 2 diabetes management, long-term weight control, and aggressive fat loss protocols.

ALSO KNOWN AS:

Retatrutide (Triple agonist: GIP, GLP-1, and Glucagon 10mg/vial)

RETATRUTIDE DOSAGE:

Triple receptor agonist – 10 mg/vial

PACKAGE CONTENT:

1 Box – 1 Vial (10 mg total content)

HOW TO USE RETATRUTIDE:

Retatrutide has a blood half-life of about 7 days, making it suitable for weekly injections. Start with 0.25–0.5 mg per week, increase gradually every 3–4 weeks depending on tolerance and goals. Typical effective range: 2–8 mg per week.

SUMMARY:

Retatrutide is a triple receptor agonist that acts on GLP-1, GIP, and glucagon receptors. It is used in the treatment of type 2 diabetes and obesity management. Retatrutide is produced in vials of 10 mg, containing the active peptide with excipients.

MECHANISM OF ACTION:

Retatrutide binds to three receptors: GLP-1, GIP, and glucagon. This triple action increases insulin secretion, reduces glucagon release, slows gastric emptying, suppresses appetite, and enhances energy expenditure. The GLP-1 and GIP pathways improve glucose control and satiety, while the glucagon pathway increases metabolic rate and fat oxidation. The combined effect is stronger blood sugar regulation, reduced food intake, and accelerated fat loss compared to single receptor agonists.

SIDE EFFECTS:

Nausea, vomiting, diarrhea, abdominal discomfort, hypoglycemia, injection site reactions, and in rare cases, gallbladder or pancreatic complications.

INTERACTIONS:

Other antidiabetic medications, insulin, and beta-blockers may alter or enhance its effects.